Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7702/7703-02E triplet therapy in BRAF V600E-mutant metastatic colorectal cancer
jRCT2080225051Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of encorafenib, binimetinib and cetuximab in colorectal cancer (CRC), sponsored by Ono Pharmaceutical. Started Feb 2020; status: completed.
02
Drugs
encorafenibbinimetinibcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2080225051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225051.